Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease
In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.
FDA Clears Phase 2 Study of Cannabis for PTSD Treatment in Veterans
After a 3-year negotiation, the FDA has cleared a phase 2 clinical trial assessing the use of smoked cannabis for the treatment of PTSD symptoms in veterans.
More than One-Third of US Adults Say They "Don't Need" Respiratory Virus Vaccines this Fall
Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.
Newly FDA-Authorized Diabetes Digital Therapeutic Can be Cost-Effective, According to Modeling Study
The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.
Rise in GLP-1 Mimetic Demand Will Continue as Pluripotency Expands
The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?
